Emgality
(Galcanezumab)ApprovedMonoclonal antibody
Eli LillyGalcanezumab is used to prevent migraines by blocking a protein in the body that causes migraine headaches. It is given as an injection and helps reduce how often migraines occur.[2] Emgality is currently approved and in use across 10 indications[4].[1]
Emgality is one of 203 monoclonal antibody programs targeting Hyperprolactinemia. It is currently in Approved.
10
Indications
31
Total Trials
6
Active Trials
202
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
357 competitors in Migraine
#DrugCompanyPhaseTrials
1Emgality
Eli LillyApproved
Aimovig
AmgenPreclinical
Vyepti
LundbeckPreclinical
Bayer Aspirin
BayerPreclinical
Savella
AbbViePreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Cervidil
PfizerPreclinical
Viagra
VViatris Specialty LLC
Preclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Migraine19 trials
Show 16 more trials
Observational Study on the Efficacy, Safety, and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly
Unknown status·—··NCT04803513·300 enrolled
Headache3 trials
Cluster headache3 trials
ART3 trials
Fibromyalgia1 trial
Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
Completed·—·Phase 4·NCT04158752·26 enrolled
Regulatory
FDA Approval Timeline[5]
Sep 27, 2018
EMGALITY
BLA BLA761063
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Emgality drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Galcanezumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]